Mariam Swidan: Hemolytic Anemia – Disease Overview
Mariam Swidan, Biomedical Science Graduate, Clinical Laboratory Professional, shared a post on LinkedIn:
“Hemolytic Anemia – Disease Overview
Definition
Hemolytic anemia is a condition characterized by premature destruction of red blood cells (RBCs), leading to a decreased RBC lifespan (less than 120 days) and insufficient compensation by the bone marrow.
Pathophysiology
- RBC destruction exceeds production
- Bone marrow responds – increased reticulocytes
- Hemoglobin breakdown – increased bilirubin
- Can occur intravascularly or extravascularly (spleen)
Classification
1. Intrinsic (RBC defect)
Usually hereditary
- Membrane defects (e.g., spherocytosis)
- Enzyme deficiencies (e.g., G6PD deficiency)
- Hemoglobinopathies (e.g., sickle cell disease, thalassemia)
2. Extrinsic (external factors)
Usually acquired
- Autoimmune hemolytic anemia
- Infections (e.g., malaria)
- Microangiopathic (DIC, TTP, HUS)
- Drugs/toxins
Clinical features
- Fatigue, pallor
- Jaundice (increased bilirubin)
- Dark urine (hemoglobinuria)
- Splenomegaly (especially extravascular)
Laboratory findings
Key pattern:
- Hb decreased
- Reticulocytes increased
- LDH increased
- Indirect bilirubin increased
- Haptoglobin decreased
Blood smear (depends on cause):
- Spherocytes
- Schistocytes
- Bite cells
Types of hemolysis
Intravascular
- RBC destruction in circulation
- Hemoglobinemia and hemoglobinuria
Extravascular
- RBC destruction in spleen/liver
- Increased splenomegaly, less hemoglobinuria
Management (depends on cause)
- Treat underlying condition
- Folic acid supplementation
- Immunosuppressants (if autoimmune)
- Splenectomy (selected cases)
- Blood transfusion if severe
The body tries to compensate for hemolysis by increasing RBC production – that’s why reticulocyte count is one of the most important markers in diagnosis.”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian